Skip to main content
Premium Trial:

Request an Annual Quote

Vela HIV, Melanoma Assays Secure Regulatory Approvals

NEW YORK (GenomeWeb) – Vela Diagnostics announced today that it has received regulatory approval for its Sentosa SQ HIV genotyping assay in Australia and its Sentosa SQ melanoma panel in Singapore.

The HIV assay runs on the company's SQ301 next-generation sequencing platform and is designed to detect HIV-1 Group M genomic mutations in protease, reverse transcriptase, and integrase regions from plasma in patients diagnosed with HIV infection. Now approved for diagnostic use by the Australian Therapeutic Goods Administration (TGA), the test is also awaiting CE-IVD marking and is being reviewed by Singapore regulators.

The melanoma panel is a next-generation sequencing-based test that screens for 127 hotspot mutations and runs on a customized Thermo Fisher Scientific Ion Torrent PGM system. It is now approved for in vitro diagnostic use by the Singapore Health Sciences Authority, and received CE-IVD status in 2014 and TGA approval in 2015.

Vela has received approvals for a number of its diagnostic assays recently, including its Sentosa SA HBV quantitative PCR test, which received CE-IVD approval in April; and its Sentosa SA ZIKV RT-PCR test, which received CE marking about a year ago.

The Scan

Less Than Half

An effort to reproduce key findings from high-profile preclinical cancer studies finds less than half could be replicated, according to the Scientist.

Still Some SARS-CoV-2 Sequencing Holes

The Wall Street Journal reports that viral genomic surveillance has improved in the US, though says there are still gaps.

Avoiding Passing Them On

People with known disease-linked genetic variants are turning to in vitro fertilization so as to not pass those variants to their children, the Washington Post says.

PNAS Papers on Long Cell-Free DNA in Maternal Plasma, Genetic Propensity for Voting

In PNAS this week: long, cell-free DNA of maternal and fetal origins identified in maternal plasma, and more.